FDA welcomes alternative approaches to generic drug development
Regulatory NewsJoanne S. Eglovitch
ComplianceNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyRegulatory NewsJoanne S. EglovitchComplianceNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy